Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$37.24 USD
-0.51 (-1.35%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $37.20 -0.04 (-0.11%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APGE 37.24 -0.51(-1.35%)
Will APGE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APGE
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
Other News for APGE
BTIG Increases Price Target for Apogee Therapeutics (APGE) to $115 | APGE Stock News
Apogee Therapeutics price target raised by $15 at BTIG, here's why
Gold Falls 1%; ProKidney Shares Spike Higher
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
12 Health Care Stocks Moving In Monday's Intraday Session